SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

11 Oct 2016 07:00

RNS Number : 1617M
Victrex PLC
11 October 2016
 
 

 

 

 

11 October 2016

Victrex plc: Full year and pre-close trading update

'Improved second half; good finish to 2016'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its full year and pre-close trading update for the financial year ended 30 September 2016, ahead of its preliminary results on 6 December 2016.

In line with expectations, Victrex delivered an improved performance in the second half and a good finish to 2016.

The core business was in growth, with Aerospace and Automotive performing well, and a more stable performance in Oil & Gas during the second half. Sales volumes for the large Consumer Electronics business were delivered on plan during Q4, with overall second half volumes more than double those in the first half. Q4, overall, saw a good performance with Group revenue up 8% to £73.7m (Q4 2015: £68.0m) and Q4 Group sales volume up 9% to 1,216 tonnes (Q4 2015: 1,119 tonnes).

Despite a positive finish to 2016, full year Group revenue declined by 4% to £252.3m (FY2015: £263.5m), reflecting the year on year fall in Consumer Electronics volumes, which were more than 30% down. Full year Group sales volume was down 6% at 3,952 tonnes (FY 2015: 4,217 tonnes).

Medical revenue (Invibio) for the full year of £50.8m (FY 2015: £50.5m) reflects a stable Spine market in the US. Growth outside of the US, in emerging markets, remains positive.

Our mega-programmes continue to make progress, with the Magma Oil & Gas project delivering first meaningful revenues of over £1m in FY16. Incremental investment opportunities aligned to our mega-programmes are also being progressed, which would further support delivery of the Group's downstream strategy and growth pipeline.

 

Outlook

 

As we start our new financial year, our core business remains robust. However, we remain mindful, as previously communicated, that our early planning assumption suggests Consumer Electronics volumes will be significantly lower in 2017, compared to 2016. This would also impact our operating leverage.

 

Whilst we will continue to invest in our 'front end' commercial, marketing and technical functions, to help drive adoption of our mega-programmes, we will also further enhance our ongoing focus on cost efficiency opportunities over the coming year.

 

With a differentiated strategy, a strong pipeline and a highly cash generative business model, Victrex remains in a good position to drive shareholder value for the medium to longer term.

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Teneo Blue Rubicon:

Charles Armitstead +44 (0) 207 260 2700

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the Automotive, Aerospace, Energy, Electronics and Medical markets. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we deliver leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGGGBUUUPQGQU
Date   Source Headline
11th Oct 20194:18 pmRNSHolding(s) in Company
8th Oct 20193:09 pmRNSHolding(s) in Company
7th Oct 20194:06 pmRNSHolding(s) in Company
3rd Oct 20194:18 pmRNSHolding(s) in Company
30th Sep 201911:53 amRNSTotal Voting Rights
18th Sep 20199:19 amRNSDirector/PDMR Shareholding
30th Aug 20199:00 amRNSTotal Voting Rights
19th Aug 201911:44 amRNSDirector/PDMR Shareholding
14th Aug 201910:39 amRNSHolding(s) in Company
31st Jul 20199:01 amRNSTotal Voting Rights
25th Jul 20197:00 amRNSInterim Management Statement
17th Jul 201910:38 amRNSDirector/PDMR Shareholding
28th Jun 20199:00 amRNSTotal Voting Rights
24th Jun 20197:00 amRNSDirectorate Change
18th Jun 201910:42 amRNSDirector/PDMR Shareholding
3rd Jun 20191:55 pmRNSBlock listing Interim Review
31st May 20193:12 pmRNSDirector/PDMR Shareholding
31st May 20199:00 amRNSTotal Voting Rights
20th May 201910:09 amRNSDirector/PDMR Shareholding
17th May 201910:50 amRNSDirector/PDMR Shareholding
15th May 20198:49 amRNSDirector/PDMR Shareholding
13th May 20197:00 amRNSHalf-year Report
30th Apr 201910:00 amRNSTotal Voting Rights
17th Apr 201912:03 pmRNSDirector/PDMR Shareholding
29th Mar 201912:07 pmRNSTotal Voting Rights
19th Mar 201910:55 amRNSDirector/PDMR Shareholding
28th Feb 20199:33 amRNSTotal Voting Rights
19th Feb 201910:42 amRNSDirector/PDMR Shareholding
18th Feb 20194:23 pmRNSDirector/PDMR Shareholding
11th Feb 20194:34 pmRNSHolding(s) in Company
8th Feb 20199:44 amRNSHolding(s) in Company
6th Feb 20192:28 pmRNSResult of AGM
6th Feb 20191:55 pmRNSDirector/PDMR Shareholding
6th Feb 20197:00 amRNSAGM and Q1 Interim Management Statement
4th Feb 201912:18 pmRNSDirector/PDMR Shareholding
31st Jan 20199:29 amRNSTotal Voting Rights
28th Jan 20194:28 pmRNSHolding(s) in Company
17th Jan 201911:21 amRNSDirector/PDMR Shareholding
11th Jan 20193:44 pmRNSHolding(s) in Company
3rd Jan 20191:00 pmRNSAnnual Financial Report
31st Dec 20189:00 amRNSTotal Voting Rights
18th Dec 20183:19 pmRNSDirector/PDMR Shareholding
18th Dec 201810:30 amRNSDirector/PDMR Shareholding
17th Dec 201811:40 amRNSDirector/PDMR Shareholding
11th Dec 20189:50 amRNSDirector/PDMR Shareholding
11th Dec 20189:48 amRNSDirector/PDMR Shareholding
5th Dec 20181:47 pmRNSDirector/PDMR Shareholding
5th Dec 201812:35 pmRNSDirector/PDMR Shareholding
4th Dec 20187:00 amRNSPreliminary Results 2018
3rd Dec 20189:25 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.